Tracking the URGN option chain helps you see every strike and expiry on UroGen Pharma Ltd in one view, so you can quickly identify the contracts that fit your thesis and your risk. UroGen Pharma Ltd's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of URGN options activity at a glance. Use our scanner to monitor the URGN option chain in real time and filter for the URGN options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For URGN stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the URGN option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where URGN stock options are being actively traded and where they are not.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer.
The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls UroGen Pharma Ltd's full chain across every expiry, highlights the most liquid strikes, and lets you screen URGN options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of URGN stock options — let the full option chain come to you, pre-filtered and ready to trade.
